AbbVie Receives U.S. FDA Priority Review for Investigational Oral Treatment Elagolix for the Management of Endometriosis with Associated Pain

FDA grants priority review to medicines it determines have potential to provide significant improvements in the safety and effectiveness of the treatment of a serious disease Priority designation shortens the review period from the standard 10 months to... Biopharmaceuticals AbbVie, Neurocrine Biosciences, elagolix, endometriosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news